glpg3970
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 10, 2019 (NCT04106297)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase SIK3INHIBITOR
SIK3 inhibitor
- Serine/threonine-protein kinase SIK2INHIBITOR
SIK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04907149 | Phase 1 | Jun 7, 2021 | Galapagos NV |
| NCT04700280 | Phase 2 | Jan 28, 2021 | Galapagos NV |
| NCT04708184 | Phase 1 | Jan 11, 2021 | Galapagos NV |
| NCT04720183 | Phase 1 | Jan 11, 2021 | Galapagos NV |
| NCT04700267 | Phase 1 | Dec 28, 2020 | Galapagos NV |
| NCT04577781 | Phase 2 | Oct 12, 2020 | Galapagos NV |
| NCT04577794 | Phase 2 | Oct 5, 2020 | Galapagos NV |
| NCT04106297 | Phase 1 | Sep 10, 2019 | Galapagos NV |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 8 | 8 | 2 | 2019 |
1 organizations
Page 1 / 1